BioSpace News Archive

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it will host a virtual KOL event on Tuesday, December 8, 2020, at 8:00 am ET.

via NewMediaWire – HearAtLast Holdings Inc., a Nevada Corporation, is pleased to announce the long anticipated integration of Crystal Clear Audio, Inc., that HearAtlast acquired in 2019.

Molecular diagnostics company Genetic Technologies Ltd (ASX: GTG; NASDAQ: GENE, the ‘Company’), announced today that they have entered into a three-year partnership agreement with mental health company, Taliaz, for the distribution rights of their PREDICTIX products in Australia, New Zealand and the USA (“Agreement”).

Taiho Oncology, Inc. and Astex Pharmaceuticals, Inc. today announced that data for oral decitabine and cedazuridine (INQOVI® [decitabine and cedazuridine] 35mg/100mg tablets) in intermediate and high-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) will be presented during the 62nd Annual American Society of Hematology Meeting and Exposition (ASH 2020),

The company joins forces with Pepper Teigen, designer Zipeng Zhu, and Asian food brand Omsom to replace outdated “No MSG” signs with new “KNOW MSG” symbol

Royal Philips, a global leader in health technology, announced its support for #BlanketChange, an advocacy campaign led by March of Dimes that calls on policymakers to improve maternal and infant health.

During the 62nd American Society of Hematology ( ASH ) Annual Meeting and Exposition, principal investigators from The US Oncology Network (The Network) and US Oncology Research will share detailed results from 30 studies covering topics that include Hodgkin lymphoma, multiple

BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ® in North America , today announced the successful completion of its acquisition by Endo International plc (End

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today that its AP-014 Phase I inhaled Ampion™ clinical study in COVID-19 patients is proceeding to full open enrollment following clearance by the

“In the era of America’s deadly opioid crisis, cutting-edge pain therapeutics like THX-160 possess the potential to be a new and effective treatment option for pain patients, reducing the risks of opiate addiction.”